Pfizer Granted FDA Breakthrough Therapy Designation for RSV Vaccine Candidate
Pfizer Inc. announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug…
Read More...
Read More...
